Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05545527
Other study ID # U32401
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date February 21, 2023
Est. completion date February 2025

Study information

Verified date May 2024
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

As a follow-up to the RAPIDIRON Trial (NCT05358509), and in combination with the RAPIDIRON-KIDS Study (NCT05504863), this study will involve infants of RAPIDIRON Trial participants recruited at one site in Karnataka and is designed to implement a magnetic resonance imaging (MRI) protocol and incorporate neuroimaging measures. Implementation of this study will promote an understanding of the effects on fetal and neonatal brain development, including iron deposition in brain tissues, when a woman is treated for iron deficiency anemia (IDA) by either (a) providing her oral iron tablets and instructions for use; or (b) administering a single-dose IV iron infusion for the treatment of IDA during pregnancy.


Description:

The hypothesis of this study is as follows: - Reduced iron availability through fetal development impacts fundamental early neurodevelopmental processes, including neurogenesis of the hippocampus, amygdala, and other 'core' deep brain basal ganglia regions (e.g., globus pallidus); and myelination of the brain's white matter connecting these deep brain structures and higher-order cortical regions involved in motor, memory, and executive functioning. The specific aims of this Neuroimaging Ancillary Study are: - To determine impact of the IV iron intervention compared to oral iron on specific markers of brain development; and - As a secondary analysis, to explore whether infant sex acts as a moderator of treatment on these specific brain development markers. This study will recruit pregnant mothers currently participating in the parent RAPIDIRON Trial, who will be approached to give consent for themselves and their offspring for participation in this Neuroimaging Ancillary Study. Participation in this Ancillary Study will involve assessments at 32-35 weeks fetal gestational age, birth, 4 months, 12 months, and 24 months post-delivery. This will involve a fetal MRI and three post-birth MRIs conducted with the offspring to collect the main neuroimaging measures. In addition, we will collect various secondary offspring and maternal measures including child auditory brain response; maternal depression, anxiety, perceived stress, and empowerment; hair cortisol; and breastmilk micronutrient analysis. Please see the protocol for additional details.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 184
Est. completion date February 2025
Est. primary completion date February 14, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - For the maternal participant in the parent RAPIDIRON Trial - a pregnancy that has not gone beyond the period for obtaining a fetal MRI (by scanning the mother at 32-35 weeks fetal gestational age) - An indication of the pregnant woman's intent to deliver in the study area and to reside there so as to be available not only to complete RAPIDIRON participation but also to allow her and her offspring to participate in ancillary study visits; - Informed consent of the pregnant RAPIDIRON participant for her participation and that of her offspring in this ancillary trial; and - Concurrent participation in the RAPIDIRON-KIDS follow-up study (NCT05504863). Exclusion Criteria: - If a fetal brain anomaly is found when the maternal participant undergoes an MRI at 32-35 weeks fetal gestational age, the dyad would be excluded from the ancillary study; - If any of the following occur, this would result in dyad ineligibility for participation or continued participation in this ancillary study: maternal blood transfusion after enrollment, a pregnancy ending in stillbirth, neonatal death, diagnosis in the offspring of moderate to severe hypoxic-ischemic encephalopathy (or HIE), and/or blood transfusion to the offspring.

Study Design


Intervention

Drug:
Ferric carboxymaltose
As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
Iron isomaltoside
As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
Ferric Sulfate
As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.

Locations

Country Name City State
India Jawaharlal Nehru Medical College Belgaum Karnataka

Sponsors (2)

Lead Sponsor Collaborator
Thomas Jefferson University Jawaharlal Nehru Medical College

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Other Child auditory brain response (ABR) results Results on auditory brain response test Birth - 4 months of age
Other Hair cortisol results Results from hair cortisol testing Birth
Other Maternal depression Maternal depression, measured via the Edinburgh Post-Natal Depression Scale Measured from 32-35 weeks fetal gestational age - 24 months offspring age
Other Maternal anxiety Maternal anxiety, measured via State-Trait Anxiety Inventory Measured from 32-35 weeks fetal gestational age - 24 months offspring age
Other Maternal Perceived Stress Maternal Perceived Stress, measured via the Perceived Stress Scale (PSS-10) Measured from 32-35 weeks fetal gestational age - 24 months offspring age
Other Maternal Empowerment Maternal empowerment, measured via the SWPER Global Survey Measured from 32-35 weeks fetal gestational age - 24 months offspring age
Other Breastmilk micronutrient analysis Breastmilk micronutrient analysis, measured via maternal breastmilk samples 4 months offspring age
Other Maternal iron status Maternal iron status, measured via hemoglobin, ferritin and TSAT 32 - 35 weeks fetal gestational age
Primary Fetal hippocampal volume Fetal hippocampus volume, measured via fetal MRI 32-35 weeks fetal gestational age
Primary Fetal diffusion parameters: fractional anisotropy (FA) Fetal white matter microstructure will be measured via FA at the posterior limb of internal capsule using fetal MRI 32-35 weeks fetal gestational age
Primary Fetal diffusion parameters: mean diffusivity Fetal white matter microstructure will be measured via MD at the posterior limb of internal capsule using fetal MRI 32-35 weeks fetal gestational age
Secondary Fetal sub-cortical gray matter structures Fetal sub-cortical gray matter structures in the brain using fetal MRI 32-35 weeks fetal gestational age
Secondary Fetal white matter microstructure measures Additional fetal white matter microstructure measures using fetal MRI, including qualitative T2 MRI measures and NODDI metrics 32-35 weeks fetal gestational age
Secondary Child hippocampal volume Child hippocampal volume, measured via MRI 4 - 24 months of age
Secondary Child white matter volume Child white matter volume, measured via MRI 4 - 24 months of age
Secondary Child white matter microstructure Child white matter microstructure, including myelination, fiber coherence, and architecture, measured via MRI 4 - 24 months of age
Secondary Child white matter connectivity Child white matter connectivity, measured via MRI 4 - 24 months of age
Secondary Child functional connectivity Child functional connectivity, measured via MRI 4 - 24 months of age
Secondary Child cerebral metabolism Child cerebral metabolism, including perfusion and spectroscopy, measured via MRI 4 - 24 months of age
See also
  Status Clinical Trial Phase
Completed NCT06315036 - Effects of Developmental Gymnastics on Preschoolers' Motor Skills N/A
Active, not recruiting NCT05143294 - Conectar Jugando: Board Games in Elementary Classrooms (6-12 Years Old) to Improve Executive Functions N/A
Completed NCT05267730 - Conectar Jugando: Board Games in Rural Elementary Classrooms (6-12 Years Old) to Improve Executive Functions N/A
Completed NCT03680157 - Comparing Rater Reliability of Familiar Practitioners to Blinded Coders
Completed NCT00362076 - The Role of Motion in Infants' Ability to Categorize N/A
Recruiting NCT05525962 - Vulnerability/Resilience Factors Influencing the Developmental Trajectories and Adaptive Methods of Children and Adolescents in Child Welfare System.
Completed NCT03232606 - Physical Activity of Asthmatic Children
Completed NCT05955755 - The Effect of Butterfly Vacuum Blood Collection Set and Standard Vacutanier Needle on the Level of Pain and Fear N/A
Recruiting NCT04443855 - WASH Benefits Child Development Follow up N/A
Not yet recruiting NCT06335524 - Infant-Maternal Partnership and Cognitive Training Study for Preterm Infants N/A
Not yet recruiting NCT05783141 - Prebiotic Effects in Healthy Toddlers N/A
Completed NCT02539251 - Arabic Ages and Stages Questionnaire-III
Completed NCT02451059 - Reducing Socioeconomic Disparities in Health at Pediatric Visits N/A
Completed NCT02800616 - The Healthy Elementary School of the Future N/A
Completed NCT02242539 - Tools to Improve Parental Recognition of Developmental Deficits in Children N/A
Completed NCT03010306 - CASITA Intervention for Children at Risk of Delay in Carabayllo, Peru N/A
Completed NCT01683565 - Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Phase 4
Completed NCT00989859 - Photo-Plethysmographic Camera to Monitor Heart Rate, Respiration Rate and Oxygen Saturation in Infants
Recruiting NCT00980733 - Efficacy of Micronutrient Fortified Yoghurt in School Children for Health Benefits Phase 3
Terminated NCT04347707 - Building Regulation in Dual Generations N/A